Bill Haney, Dragonfly

Ab­b­Vie lines up a new pre­clin­i­cal R&D al­liance with the deal­mak­ers at nat­ur­al killer play­er Drag­on­fly

Bill Haney is build­ing on his rep as one of the most pro­lif­ic deal­mak­ers in pre­clin­i­cal R&D, adding a new al­liance for Drag­on­fly Ther­a­peu­tics with Ab­b­Vie on can­cer drugs as well as au­toim­mune dis­eases — a new field for the up­start de­vel­op­er.

As is gen­er­al­ly the case with Drag­on­fly, hard num­bers are scarce, but Cel­gene, Mer­ck and Ab­b­Vie have front­ed about $200 mil­lion in cash so far, says the CEO, with more than $7 bil­lion in mile­stones. Haney’s oth­er biotech is Sky­hawk, a pop­u­lar play­er in the field of drug­ging RNA, which has grabbed $350 mil­lion to $400 mil­lion in up­front pay­ments and more than $15 bil­lion in mile­stones from a slate of part­ners.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.